Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Nothing like some 'leaks' on the FDA Resubmission

<< Previous

Bullboard Posts

Next >>

Comment by Kd5513on Apr 28, 2023 12:58pm

56 Views

Post# 35419488

RE:RE:RE:RE:RE:RE:RE:Nothing like some 'leaks' on the FDA Resubmission

The reason they are not posting a PR is becuase they are going to miss their promised date of end of April by about 5 weeks and not have submitted until right before next Q CC so tehy can say yes we submitted to FDA and should hear back shortly.....they will just omit that they sent over 18 minutes before the CC call started.

Sadly I think that is the reality of why no PR, otherwise they are just incompetent and missing another opportunity to communcate to market and drive the conversation. Its one or the other IMO.

<< Previous

Bullboard Posts

Next >>

Parliament looks for your word on potential Chinese-made EV tariffs